IL273485B2 - Enhanced delivery epinephrine and prodrug compositions - Google Patents
Enhanced delivery epinephrine and prodrug compositionsInfo
- Publication number
- IL273485B2 IL273485B2 IL273485A IL27348520A IL273485B2 IL 273485 B2 IL273485 B2 IL 273485B2 IL 273485 A IL273485 A IL 273485A IL 27348520 A IL27348520 A IL 27348520A IL 273485 B2 IL273485 B2 IL 273485B2
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- composition according
- polymeric matrix
- ester
- acceptable salt
- Prior art date
Links
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 title claims 19
- 229930182837 (R)-adrenaline Natural products 0.000 title claims 19
- 229960005139 epinephrine Drugs 0.000 title claims 19
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 48
- 239000011159 matrix material Substances 0.000 claims 26
- 150000002148 esters Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 12
- 102000017910 Adrenergic receptor Human genes 0.000 claims 12
- 239000010408 film Substances 0.000 claims 11
- 229920000642 polymer Polymers 0.000 claims 8
- 229930015704 phenylpropanoid Natural products 0.000 claims 6
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 claims 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 5
- 241000196324 Embryophyta Species 0.000 claims 4
- 244000061408 Eugenia caryophyllata Species 0.000 claims 4
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims 4
- 150000004676 glycans Chemical class 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 239000003961 penetration enhancing agent Substances 0.000 claims 4
- 229920001282 polysaccharide Polymers 0.000 claims 4
- 239000005017 polysaccharide Substances 0.000 claims 4
- 239000000341 volatile oil Substances 0.000 claims 4
- 229920001577 copolymer Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 2
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 claims 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims 2
- 239000005770 Eugenol Substances 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims 2
- 235000010489 acacia gum Nutrition 0.000 claims 2
- RGIBXDHONMXTLI-UHFFFAOYSA-N chavicol Chemical compound OC1=CC=C(CC=C)C=C1 RGIBXDHONMXTLI-UHFFFAOYSA-N 0.000 claims 2
- 229930016911 cinnamic acid Natural products 0.000 claims 2
- 235000013985 cinnamic acid Nutrition 0.000 claims 2
- 229960002217 eugenol Drugs 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- 208000003663 ventricular fibrillation Diseases 0.000 claims 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 208000037874 Asthma exacerbation Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- IAZKGRRJAULWNS-UHFFFAOYSA-N Chavicol Natural products OC1=CC=C(CCC=C)C=C1 IAZKGRRJAULWNS-UHFFFAOYSA-N 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
- 208000006550 Mydriasis Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- 206010058151 Pulseless electrical activity Diseases 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000001851 biosynthetic effect Effects 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000036471 bradycardia Effects 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- -1 cinnamic acid ester Chemical class 0.000 claims 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims 1
- 229940117916 cinnamic aldehyde Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229930002886 farnesol Natural products 0.000 claims 1
- 229940043259 farnesol Drugs 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920000587 hyperbranched polymer Polymers 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical class N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- 229930004725 sesquiterpene Natural products 0.000 claims 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 235000007586 terpenes Nutrition 0.000 claims 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 208000021816 ventricular bradycardia Diseases 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/717,859 US20180125977A1 (en) | 2016-05-05 | 2017-09-27 | Enhanced delivery epinephrine compositions |
| US15/791,249 US12427121B2 (en) | 2016-05-05 | 2017-10-23 | Enhanced delivery epinephrine compositions |
| PCT/US2018/053042 WO2019067670A1 (en) | 2017-09-27 | 2018-09-27 | EPINEPHRINE AND ENHANCED DELIVERY COMPOSITIONS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL273485A IL273485A (en) | 2020-05-31 |
| IL273485B1 IL273485B1 (en) | 2024-07-01 |
| IL273485B2 true IL273485B2 (en) | 2024-11-01 |
Family
ID=63858169
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273485A IL273485B2 (en) | 2017-09-27 | 2018-09-27 | Enhanced delivery epinephrine and prodrug compositions |
| IL313551A IL313551A (en) | 2017-09-27 | 2018-09-27 | Enhanced delivery epinephrine and prodrug compositions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313551A IL313551A (en) | 2017-09-27 | 2018-09-27 | Enhanced delivery epinephrine and prodrug compositions |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3687510A1 (enExample) |
| JP (2) | JP2020535162A (enExample) |
| KR (1) | KR20200060748A (enExample) |
| CN (1) | CN111465391A (enExample) |
| BR (1) | BR112020005948A2 (enExample) |
| CA (1) | CA3076816A1 (enExample) |
| IL (2) | IL273485B2 (enExample) |
| WO (1) | WO2019067670A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| KR20230137362A (ko) | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| AU2020373100A1 (en) * | 2019-11-01 | 2022-05-19 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| US11571468B2 (en) * | 2021-02-01 | 2023-02-07 | Matthias W. Rath | Micronutrient combination to reduce blood pressure |
| WO2023076281A1 (en) | 2021-10-25 | 2023-05-04 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
| US20240016734A1 (en) * | 2022-06-14 | 2024-01-18 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| EP4302751A1 (en) * | 2022-07-07 | 2024-01-10 | LTS Lohmann Therapie-Systeme AG | Oral thin films with low water activity |
| CN118121542A (zh) * | 2023-03-31 | 2024-06-04 | 中国药科大学 | 鼻用药物组合物、其制备方法及应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070202163A1 (en) * | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| WO2017192923A1 (en) * | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Pharmaceutical compositions with enhanced permeation |
| WO2017192921A1 (en) * | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Enhanced delivery epinephrine compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20030143195A1 (en) * | 2002-01-30 | 2003-07-31 | Pinsker Judy Senior | Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
| US20040096569A1 (en) * | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| US20050266085A1 (en) * | 2004-05-28 | 2005-12-01 | Warner Kevin S | Gelled emulsion and microemulsion formulations for dermal drug delivery |
| IL175338A0 (en) * | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
| TW200815048A (en) * | 2006-06-05 | 2008-04-01 | Verus Pharmaceuticals Inc | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
| US20070293582A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
| PE20091084A1 (es) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal |
| WO2010122355A1 (en) * | 2009-04-23 | 2010-10-28 | Londonpharma Ltd. | Sublingual pharmaceutical composition comprising a neutral oil |
| EP2552486B1 (en) * | 2010-03-30 | 2020-08-12 | Phosphagenics Limited | Transdermal delivery patch |
| WO2013063614A1 (en) * | 2011-10-28 | 2013-05-02 | Sung-Yun Kwon | Dissolving solid solution perforator patch for migraine treatment |
| NZ706302A (en) * | 2012-10-11 | 2017-07-28 | Ix Biopharma Ltd | Sublingual wafer solid dosage form containing amylopectin |
| US20160051494A1 (en) * | 2014-08-21 | 2016-02-25 | Mylan, Inc. | Multi-dose medication kit for treating anaphylaxis |
| CA3076751A1 (en) * | 2017-09-26 | 2019-04-04 | Aquestive Therapeutics, Inc. | Delivery pharmaceutical compositions including permeation enhancers |
-
2018
- 2018-09-27 EP EP18786593.6A patent/EP3687510A1/en active Pending
- 2018-09-27 CN CN201880063175.3A patent/CN111465391A/zh active Pending
- 2018-09-27 IL IL273485A patent/IL273485B2/en unknown
- 2018-09-27 IL IL313551A patent/IL313551A/en unknown
- 2018-09-27 BR BR112020005948-0A patent/BR112020005948A2/pt unknown
- 2018-09-27 CA CA3076816A patent/CA3076816A1/en active Pending
- 2018-09-27 WO PCT/US2018/053042 patent/WO2019067670A1/en not_active Ceased
- 2018-09-27 JP JP2020517419A patent/JP2020535162A/ja active Pending
- 2018-09-27 KR KR1020207012106A patent/KR20200060748A/ko not_active Ceased
-
2023
- 2023-08-03 JP JP2023126682A patent/JP2023159150A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070202163A1 (en) * | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| WO2017192923A1 (en) * | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Pharmaceutical compositions with enhanced permeation |
| WO2017192921A1 (en) * | 2016-05-05 | 2017-11-09 | Monosol Rx, Llc | Enhanced delivery epinephrine compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| IL273485B1 (en) | 2024-07-01 |
| IL313551A (en) | 2024-08-01 |
| IL273485A (en) | 2020-05-31 |
| JP2020535162A (ja) | 2020-12-03 |
| WO2019067670A1 (en) | 2019-04-04 |
| CN111465391A (zh) | 2020-07-28 |
| JP2023159150A (ja) | 2023-10-31 |
| BR112020005948A2 (pt) | 2020-12-01 |
| KR20200060748A (ko) | 2020-06-01 |
| EP3687510A1 (en) | 2020-08-05 |
| CA3076816A1 (en) | 2019-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273485B1 (en) | Enhanced delivery epinephrine and prodrug compositions | |
| JP2020535162A5 (enExample) | ||
| IL273479B1 (en) | Pharmaceutical compositions with enhanced permeation | |
| JP2020535176A5 (enExample) | ||
| JP2019519487A5 (enExample) | ||
| RU2016151163A (ru) | Композиции, включающие электрогидродинамически полученные волокна, для нанесения заданных доз активного вещества на кожу или слизистую оболочку | |
| Hamman et al. | Use of natural gums and mucilages as pharmaceutical excipients | |
| CN102068474B (zh) | 刺山柑果凝胶膏剂及其生产方法和抗风湿药物的应用 | |
| ES2879892T3 (es) | Uso de una solución banda resistente a los ácidos para sellar cápsulas duras de dos piezas | |
| CN101062289A (zh) | 治疗痛风的外用药物组合物 | |
| CN110787150A (zh) | 一种含有氟比洛芬的皮肤外用制剂 | |
| CN102085176A (zh) | 一种纳米级伊曲康唑外用制剂、其制备方法及其用途 | |
| CN103908484B (zh) | 一种用于治疗类风湿性关节炎的雷公藤涂膜剂及其制备方法 | |
| WO2014124504A1 (en) | Compositions and methods for treating biofilms | |
| Saettone | Solid polymeric inserts/disks as drug delivery devices | |
| CN110090294A (zh) | 具有改善的干燥保护和保留的眼用组合物 | |
| Kumar et al. | Natural excipients: A review | |
| CN1302813C (zh) | 含海藻糖和透明质酸的烧伤用药传递系统及其制备方法 | |
| ES2349295T3 (es) | Forma galénica sólida para la administración ocular de un principio activo, inserto oftálmico sólido y soluble y procedimiento de fabricación de un inserto de este tipo. | |
| CN114376964B (zh) | 一种葛根素纳米粒成膜水凝胶制剂及其制备方法 | |
| CN1403158A (zh) | 含壳聚糖衍生物的滴眼液 | |
| Puri et al. | An Update on some recent solubility enhancers as pharmaceutical excipients | |
| RU2536958C2 (ru) | Лекарственное средство для лечения катаракты и способ его получения (варианты) | |
| Milinković et al. | Hypromellose-based films and film-forming systems for topical application: current status and perspective in drug delivery | |
| CN1634118A (zh) | 含有多糖聚阴离子锌盐的抗病毒制剂及其制备方法 |